Paroxetine's Effects on Quality of Life in Diabetics with Mild Depression
Author Information
Author(s): Maria Paile-Hyvärinen, Kristian Wahlbeck, Johan G Eriksson
Primary Institution: National Public Health Institute, Helsinki, Finland
Hypothesis
Does paroxetine improve quality of life and metabolic control in mildly depressed patients with type 2 diabetes?
Conclusion
Paroxetine did not show a sustained beneficial effect on glycaemic control or quality of life in mildly depressed diabetic patients.
Supporting Evidence
- Paroxetine showed a significant improvement in GHbA1c after three months.
- Quality of life improved significantly in the paroxetine group compared to placebo at three months.
- No severe adverse events were reported during the study.
Takeaway
This study looked at whether a medicine called paroxetine could help people with diabetes and mild depression feel better. It found that while it helped a little at first, the benefits didn't last.
Methodology
49 mildly depressed type 2 diabetes patients were randomly assigned to receive either paroxetine or placebo for 6 months, with assessments of quality of life and metabolic control.
Potential Biases
Potential bias due to the study being investigator-initiated and the involvement of a pharmaceutical company in providing the medication.
Limitations
The study's findings may not apply to patients with moderate to severe depression, and the effects of paroxetine were not sustained over time.
Participant Demographics
Participants were mildly depressed adults aged 50-70 with type 2 diabetes.
Statistical Information
P-Value
0.018
Confidence Interval
95% CI not specified
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website